Workflow
Neuroinflammation treatment
icon
Search documents
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025
Globenewswire· 2025-07-28 12:05
Core Viewpoint - NKGen Biotech's Troculeucel shows promise in treating Alzheimer's disease by enhancing neuroinflammation modulation and improving cognitive function in patients, as evidenced by clinical trial data presented at AAIC 2025 [1][9]. Company Overview - NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative autologous and allogeneic natural killer (NK) cell therapeutics [12]. - The company is headquartered in Santa Ana, California, and is advancing Troculeucel for neurodegenerative disorders and various cancers [13]. Product Details - Troculeucel is a first-in-kind, autologous, non-genetically modified NK cell product with over 90% activating receptor expression and significantly increased cytotoxicity [2]. - The product has shown the ability to internalize and degrade amyloid and α-synuclein aggregates in vitro, indicating its potential effectiveness in Alzheimer's disease [5]. Clinical Trial Findings - In Phase 1 studies, 92% of patients (12 out of 13) exhibited stable or improved Alzheimer's Disease Composite Score (ADCOMS) after three months of treatment [7][14]. - Notably, two patients with moderate Alzheimer's improved to mild-stage after receiving the highest dose of Troculeucel [7]. - Biomarker data indicated that 60%, 90%, and 70% of patients showed stabilization or improvement in CSF levels of Aβ42/40, p-Tau181, and α-synuclein, respectively, after three months [5]. Mechanism of Action - Troculeucel demonstrates high expression of receptors involved in modulating neuroinflammation, including 91.25% CXCR3 expression, which facilitates migration towards the CSF in Alzheimer's patients [3][10]. - The therapy selectively targets autoreactive T cells while sparing resting T cells, potentially reducing neuroinflammation [4][9]. Additional Observations - Six out of ten patients showed decreased levels of Glial Fibrillary Acid Protein (GFAP) after three months, indicating a reduction in neuroinflammation [6]. - The findings suggest that Troculeucel may have broader applications for other neurodegenerative diseases beyond Alzheimer's [9].